Delivery of A Vector with Vascular Endothelial Growth Factor Gene to the Pluripotent Stem Cell for Gene Therapy

Angiogenesis is a crucial event during endochondral ossification. Deficiencies in vascularity will lead to a delayed union, nonunion or necrosis. Vascular endothelial growth factor (VEGF) is one of the key regulators of angiogenesis. VEGF may play key roles in the regulation of angiogenesis at sites that processing endochondral bone formation. The local release of VEGF from the osteogenic cells at the site or near the necrotic bone may also enhance the repair of osteonecrosis. We proposed that the transplantation of osteoprogenitor cells transfected with VEGF gene would be beneficial for the therapy of fracture repair and osteonecrosis. This study was designed to transfect the VEGF gene into the pluripotent stem cell (Dl cell), and test the potential for gene therapy in vitro. We examined the expressions of mRNA and protein of VEGF, and its bioactivity in Dl cells that transfected with VEGF containing vector. Our results showed that the transfected cells expressed the significant higher level of mRNA, protein and bioactivity of VEGF in comparison with the vector controlled or non-transfected Dl cells. These results showed that the VEGF transfected Dl cells could stably produce the bioactive VEGF. Our results also revealed that the transfected Dl cell still preserve the osteogenic characteristic. This phenomenon ensures that the transfection does not change the phenotype or the capacity of stem cells to differentiation into osteoblasts. These results suggested that VEGF transfected Dl cell can be used as a carrier for gene therapy of fracture repair and osteonecrosis.

並列關鍵字

vascular endothelial growth factor ； stem cell ； gene therapy

國際替代計量

全文下載

主題瀏覽